Metastatic pancreatic cancer is notoriously difficult to treat due to late detection and the aggressive nature of the disease, which accounts for a disproportionately high share of cancer deaths despite representing only about 3.2% of all cancer diagnoses in the U.S. The approval follows a “Breakthrough Therapy” designation granted in June 2025 and an expanded access approval in May 2026. Dr. Brian Wolpin, director of the Hale Family Center for Pancreatic Cancer Research at the Dana-Farber Cancer Institute, described the approval as an “exceptional moment,” noting it provides a new foundation for advances against the disease.
Daraxonrasib operates as a pan-RAS inhibitor, a new class of drug that targets multiple forms of the RAS protein. Unlike previous approaches that struggled to find a binding site on the flat surface of the KRAS protein, daraxonrasib uses a tricomplex binding mechanism. It binds to a chaperone protein to create a “sandwich” structure, effectively creating its own binding pocket to inhibit the seven known cancer-causing KRAS mutations. This engineering approach allows the drug to address the “stuck” growth switch in over 90% of pancreatic cancer cases.
Clinical data indicates the treatment offers tangible quality-of-life benefits. Dr. Pashtoon Kasi, a medical oncologist at City of Hope and principal investigator of the expanded access trials, reported that the drug worked for nearly every patient in the study, a response rate uncommon in this field. He noted that some patients were able to stop taking pain medications, a significant improvement over chemotherapy experiences. The most common side effect reported was a skin rash, which is generally milder than the toxicities associated with standard chemotherapy infusions. As an oral pill, it also offers greater convenience for patients.
The mechanism of action, which targets KRAS mutations, suggests potential applications beyond pancreatic cancer. Clinical trials are currently underway to determine if the drug benefits patients with lung and colorectal cancers, which are also driven by similar genetic mechanisms. However, the high cost of the treatment remains a barrier; Revolution Medicines has set the wholesale price at nearly $40,000 per month, with actual patient costs depending on insurance coverage. The approval expands the limited treatment options for a disease that remains the third-leading cause of cancer deaths in the United States, killing nearly 53,000 people annually.
